A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
Clinical trial NCT04809467 · TERMINATED
Trial details
- NCT number
- NCT04809467
- Sponsor
- Incyte Corporation
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-16
- Primary completion
- 2024-10-22
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.